An Open-label, Pilot Clinical Trial of Dalbavancin for the Treatment of Susceptible Gram-positive Infections Requiring Prolonged Intravenous Antibiotic Therapy
Latest Information Update: 05 May 2023
At a glance
- Drugs Dalbavancin (Primary)
- Indications Bacteraemia; Bacterial endocarditis; Bone and joint infections; Gram-positive infections
- Focus Therapeutic Use
- 01 May 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 29 Jun 2022 Planned End Date changed from 1 Jul 2023 to 1 Jul 2025.
- 29 Jun 2022 Planned primary completion date changed from 1 Apr 2023 to 1 Apr 2025.